| pubmed-article:17982680 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17982680 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:17982680 | lifeskim:mentions | umls-concept:C0012655 | lld:lifeskim |
| pubmed-article:17982680 | lifeskim:mentions | umls-concept:C0023467 | lld:lifeskim |
| pubmed-article:17982680 | lifeskim:mentions | umls-concept:C1512474 | lld:lifeskim |
| pubmed-article:17982680 | lifeskim:mentions | umls-concept:C0205245 | lld:lifeskim |
| pubmed-article:17982680 | lifeskim:mentions | umls-concept:C1521970 | lld:lifeskim |
| pubmed-article:17982680 | lifeskim:mentions | umls-concept:C0805527 | lld:lifeskim |
| pubmed-article:17982680 | lifeskim:mentions | umls-concept:C2266853 | lld:lifeskim |
| pubmed-article:17982680 | lifeskim:mentions | umls-concept:C1956267 | lld:lifeskim |
| pubmed-article:17982680 | lifeskim:mentions | umls-concept:C1515021 | lld:lifeskim |
| pubmed-article:17982680 | lifeskim:mentions | umls-concept:C0205225 | lld:lifeskim |
| pubmed-article:17982680 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:17982680 | pubmed:dateCreated | 2007-11-5 | lld:pubmed |
| pubmed-article:17982680 | pubmed:abstractText | Modulation of gene expression through histone deacetylase (HDAC) inhibition is considered a possible therapeutic strategy in acute myeloid leukaemia (AML). In vitro effects and basal gene expression of structurally different HDAC inhibitors were examined. Primary human AML cells were derived from 59 consecutive patients. The HDAC inhibitors valproic acid, PXD101, trichostatin A and sodium butyrate inhibited leukaemic and clonogenic cell proliferation and increased apoptosis in a dose-dependent manner when tested at high concentrations. However, at lower concentrations proliferation increased for a subset of patients. This divergence was also observed in the presence of all-trans retinoic acid, theophylline and decitabine, and in cocultures with bone marrow stromal cells. Levels of IL-1beta, IL-6, GM-CSF and TNFalpha increased. Based on the basal expression of 100 genes the patients with growth enhancement at intermediate HDAC inhibitor concentrations and those without this response were clustered into two mutually exclusive groups. Functional characterization and gene expression analyses identify AML patient subsets that differ in their response to HDAC inhibitors. These observations may explain why HDAC inhibitor therapy affects only a subset of patients. | lld:pubmed |
| pubmed-article:17982680 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17982680 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17982680 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17982680 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17982680 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17982680 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17982680 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17982680 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17982680 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17982680 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17982680 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:17982680 | pubmed:issn | 1019-6439 | lld:pubmed |
| pubmed-article:17982680 | pubmed:author | pubmed-author:BruserudØyste... | lld:pubmed |
| pubmed-article:17982680 | pubmed:author | pubmed-author:CorbascioMatt... | lld:pubmed |
| pubmed-article:17982680 | pubmed:author | pubmed-author:GjertsenBjørn... | lld:pubmed |
| pubmed-article:17982680 | pubmed:author | pubmed-author:StapnesCamill... | lld:pubmed |
| pubmed-article:17982680 | pubmed:author | pubmed-author:KallandKarl-H... | lld:pubmed |
| pubmed-article:17982680 | pubmed:author | pubmed-author:EideGeir... | lld:pubmed |
| pubmed-article:17982680 | pubmed:author | pubmed-author:RyningenAnita... | lld:pubmed |
| pubmed-article:17982680 | pubmed:author | pubmed-author:HatfieldKimbe... | lld:pubmed |
| pubmed-article:17982680 | pubmed:author | pubmed-author:ØyanAnne... | lld:pubmed |
| pubmed-article:17982680 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17982680 | pubmed:volume | 31 | lld:pubmed |
| pubmed-article:17982680 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17982680 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17982680 | pubmed:pagination | 1529-38 | lld:pubmed |
| pubmed-article:17982680 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:17982680 | pubmed:meshHeading | pubmed-meshheading:17982680... | lld:pubmed |
| pubmed-article:17982680 | pubmed:meshHeading | pubmed-meshheading:17982680... | lld:pubmed |
| pubmed-article:17982680 | pubmed:meshHeading | pubmed-meshheading:17982680... | lld:pubmed |
| pubmed-article:17982680 | pubmed:meshHeading | pubmed-meshheading:17982680... | lld:pubmed |
| pubmed-article:17982680 | pubmed:meshHeading | pubmed-meshheading:17982680... | lld:pubmed |
| pubmed-article:17982680 | pubmed:meshHeading | pubmed-meshheading:17982680... | lld:pubmed |
| pubmed-article:17982680 | pubmed:meshHeading | pubmed-meshheading:17982680... | lld:pubmed |
| pubmed-article:17982680 | pubmed:meshHeading | pubmed-meshheading:17982680... | lld:pubmed |
| pubmed-article:17982680 | pubmed:meshHeading | pubmed-meshheading:17982680... | lld:pubmed |
| pubmed-article:17982680 | pubmed:meshHeading | pubmed-meshheading:17982680... | lld:pubmed |
| pubmed-article:17982680 | pubmed:meshHeading | pubmed-meshheading:17982680... | lld:pubmed |
| pubmed-article:17982680 | pubmed:meshHeading | pubmed-meshheading:17982680... | lld:pubmed |
| pubmed-article:17982680 | pubmed:meshHeading | pubmed-meshheading:17982680... | lld:pubmed |
| pubmed-article:17982680 | pubmed:meshHeading | pubmed-meshheading:17982680... | lld:pubmed |
| pubmed-article:17982680 | pubmed:meshHeading | pubmed-meshheading:17982680... | lld:pubmed |
| pubmed-article:17982680 | pubmed:meshHeading | pubmed-meshheading:17982680... | lld:pubmed |
| pubmed-article:17982680 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17982680 | pubmed:articleTitle | Functional characteristics and gene expression profiles of primary acute myeloid leukaemia cells identify patient subgroups that differ in susceptibility to histone deacetylase inhibitors. | lld:pubmed |
| pubmed-article:17982680 | pubmed:affiliation | Institute of Medicine, University of Bergen/Haukeland University Hospital, N-5021, Bergen, Norway. camilla.ingvaldsen.stapnes@helse-bergen.no | lld:pubmed |
| pubmed-article:17982680 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17982680 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17982680 | lld:pubmed |
